DealBook: Merck Bids $3.8 Billion for an Edge in Hepatitis
Tuesday, June 10, 2014 - 00:20
in Mathematics & Economics
Merck will pay $24.50 a share in cash, or about $3.85 billion, for the biotechnology company Idenix in an effort to bolster its arsenal of potential drugs in the hotly competitive hepatitis C area.